On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements for NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine. The companies have agreed that SK bioscience will reserve significant additional manufacturing capacity to produce antigen, a key component of NVX-CoV2373, through 2022, with the possibility to extend the arrangement.

Additionally, SK bioscience has acquired non-exclusive rights to sell doses of Novavax’ vaccine to the governments of Thailand and Vietnam.